The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
COVID-19: U.S. Impact on Antimicrobial Resistance, Special Report 2022
Open accessAbstract
CDC’s COVID-19: U.S. Impact on Antimicrobial Resistance, Special Report 2022, provides a snapshot of how the COVID-19 pandemic impacted antimicrobial resistance in the United States. Data have shown national progress in slowing the spread of antimicrobial resistance and preventing these infections is possible. However, the pandemic has undone much of the nation’s progress on antimicrobial resistance, especially in hospitals. CDC’s Special Report highlights the impact of COVID-19 on five core to combat antimicrobial resistance and on 18 pathogens, identified by CDC as urgent, serious, and concerning threats. The United States must continue to invest in the prevention-focused public health actions to combat antimicrobial resistance. CDC’s Antimicrobial Resistance Solutions Initiative has invested in domestic and global capacity to detect, respond, contain, and prevent the spread of resistance across health care, food, environment, and communities. These investments are working, but more work is needed. This was emphasized by the COVID-19 pandemic. CDC is exploring investments needed moving forward in the U.S. and global public health infrastructure to ensure a simultaneous response to the challenges of antimicrobial resistance and other emerging threats. The United States must continue to invest in preparing public health systems to address threats from multiple angles, simultaneously, and across One Health. If properly resourced, the United States can continue to build resilient domestic and global public health systems to keep our nation safe against the threats of antimicrobial-resistant pathogens. COVID-19: U.S. Impact on Antimicrobial Resistance, Special Report 2022, is a publication of the Antimicrobial Resistance Coordination and Strategy Unit within the Division of Healthcare Quality Promotion, National Center for Emerging and Zoonotic Infectious Diseases, Centers for Disease Control and Prevention. Suggested citation: CDC. COVID-19: U.S. Impact on Antimicrobial Resistance, Special Report 2022. Atlanta, GA: U.S. Department of Health and Human Services, CDC; 2022. https://www.cdc.gov/drugresistance/covid19.html
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Robust Inference With Multiway Clustering
Cameron, A. C., Gelbach, J. B., & Miller, D. L. (2011) · Journal of Business & Economic Statistics · doi:10.1198/jbes.2010.07136 · Cited by 3,203
Lockhart, S. R., Etienne, K. A., Vallabhaneni, S., Farooqi, J., Chowdhary, A., Govender, N. P., Colombo, A. L., Calvo, B., Cuomo, C. A., Desjardins, C. A., et al. (2017) · Clinical Infectious Diseases · doi:10.1093/cid/ciw691 · Cited by 1,662
Chow, N. A., Gade, L., Tsay, S. V., Forsberg, K., Greenko, J. A., Southwick, K. L., Barrett, P. M., Kerins, J. L., Lockhart, S. R., Chiller, T. M., et al. (2018) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(18)30597-8 · Cited by 289
Candida auris Outbreak in a COVID-19 Specialty Care Unit — Florida, July–August 2020
Prestel, C., Anderson, E., Forsberg, K., Lyman, M., de Perio, M. A., Kuhar, D., Edwards, K., Rivera, M., Shugart, A., Walters, M., et al. (2021) · MMWR. Morbidity and Mortality Weekly Report · doi:10.15585/mmwr.mm7002e3 · Cited by 237
Cited by
Quaternary Ammonium Compounds: A Chemical Class of Emerging Concern
Arnold, W. A., Blum, A., Branyan, J., Bruton, T. A., Carignan, C. C., Cortopassi, G., Datta, S., DeWitt, J., Doherty, A.-C., Halden, R. U., et al. (2023) · Environmental Science & Technology · doi:10.1021/acs.est.2c08244 · Cited by 391
Trends in empiric broad-Spectrum antibiotic use for suspected community-onset Sepsis in US hospitals
Rhee, C., Chen, T., Kadri, S. S., Lawandi, A., Yek, C., Walker, M., Warner, S., Fram, D., Chen, H.-C., Shappell, C. N., et al. (2024) · JAMA Network Open · doi:10.1001/jamanetworkopen.2024.18923 · Cited by 58
(2023) · doi:10.1038/s41467-023-43702-4 · Cited by 55
Metadata
- Published
- 2022-06-14
- OpenAlex
- W4281842559
- Cited by
- 182
- References
- 4
- Type
- report
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: COVID-19: U.S. Impact on Antimicrobial Resistance, Special Report 2022. https://app.cochat.ai/papers/10.15620/cdc:117915
- The paper
- COVID-19: U.S. Impact on Antimicrobial Resistance, Special Report 2022. (2022). https://doi.org/10.15620/cdc%3A117915
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
